Each year, more than eighty thousand children under five are lost to sickle cell disease — a largely preventable toll borne most heavily by families in sub-Saharan Africa, where medicine, diagnosis, and care remain distant promises. The World Health Organization has now issued its first dedicated clinical guidelines for children with the condition and opened a formal pathway for manufacturers to bring child-friendly hydroxyurea formulations into quality-assured supply. It is a recognition, long overdue, that knowing a cure exists and placing it in a child's hands are two entirely different thi
WHO Prioritizes Child-Friendly Sickle Cell Medicines to Close Global Treatment Gap
Approximately 81,100 children under five died from sickle cell disease in 2021, with millions more facing delayed diagnosis, medicine shortages, and preventable complications across sub-Saharan Africa and other high-burden regions.
A child's birthplace should not decide whether treatment is available
Mark
Why does sickle cell disease kill so many children in sub-Saharan Africa when treatments exist elsewhere?
Mimi
The disease itself is deadly, but what kills children in high-burden countries is the gap between what medicine can do and what families can actually access. Diagnosis comes late, medicines are scarce or unaffordable, and health systems lack the resources for ongoing care.
Luke
So the 81,100 deaths—is that a firm count or an estimate?
Mimi
It's an estimate from 2021. The actual number could be higher, but that's the figure the WHO is working from.
Mark
What makes hydroxyurea different from other treatments?
Mimi
It reduces painful crises and prevents serious complications. It's not a cure, but it lets children live substantially healthier lives. The problem is that existing formulations aren't designed for children—they're hard to swallow, expensive, and dosing is difficult as kids grow.
Luke
And the new Target Product Profile—does that guarantee manufacturers will actually make child-friendly versions?
Mimi
No. It sets out what the WHO thinks should exist. The Prequalification pathway opens a route for manufacturers to submit formulations for quality evaluation, but it doesn't compel production or set prices.
Mark
What happens next?
Mimi
The WHO is waiting to see which manufacturers engage with the prequalification process. Meanwhile, two networks—GAP-f and OneSCD—are supposed to coordinate action among governments, health systems, and other actors to actually implement the guidelines.
Luke
And if coordination doesn't happen?
Mimi
Then the guidelines remain recommendations on paper, and children continue to die from a preventable disease.
El Pulso
- An estimated 81,100 children under five die from sickle cell disease every year, nearly 80% of them in sub-Saharan Africa, where treatment access is crippled by cost, shortages, and overstretched health systems.
- WHO's landmark 2026 guidelines now recommend hydroxyurea for every child with sickle cell anaemia from as young as nine months — regardless of symptom severity — marking a decisive shift toward early, universal intervention.
- The gap between recommendation and reality is stark: existing hydroxyurea formulations are often impossible for young children to swallow, unaffordable for low-income families, and unstable in tropical climates where the disease is most prevalent.
- A newly published Target Product Profile and WHO's first Prequalification Expression of Interest for paediatric sickle cell treatments create a concrete quality-assurance route for manufacturers, giving governments the confidence to procure and deploy these medicines at scale.
- The road ahead demands synchronized action — governments, manufacturers, funders, and global networks like GAP-f and the forthcoming OneSCD partnership must now convert WHO guidance into medicines that reliably reach the children who need them most.
Each year, more than eighty thousand children under five are lost to sickle cell disease — a largely preventable toll borne most heavily by families in sub-Saharan Africa, where medicine, diagnosis, and care remain distant promises. The World Health Organization has now issued its first dedicated clinical guidelines for children with the condition and opened a formal pathway for manufacturers to bring child-friendly hydroxyurea formulations into quality-assured supply. It is a recognition, long overdue, that knowing a cure exists and placing it in a child's hands are two entirely different things — and that the distance between them is measured not in science, but in will, coordination, and equity.
Every year, sickle cell disease claims roughly 81,100 children before their fifth birthday. Nearly four in five of those deaths occur in sub-Saharan Africa, where children who could survive with proper treatment instead face delayed diagnosis, empty pharmacy shelves, and health systems too strained to provide lifelong care. The World Health Organization has now released clinical guidelines and a concrete supply pathway designed to close that gap — moving effective medicines from the realm of the known-but-unreachable into the hands of families in the countries where the burden falls hardest.
Sickle cell disease is the world's most common inherited blood disorder, distorting red blood cells and triggering cascades of pain, anaemia, stroke, organ failure, and early death. It strikes across the globe but weighs most heavily on low- and middle-income countries. A child diagnosed early and given access to vaccination, monitoring, and disease-modifying treatment can live a substantially healthier life — yet those services remain financially and logistically out of reach for most affected families.
In May 2026, WHO published its first guideline dedicated entirely to sickle cell disease in children and adolescents up to age nineteen. Its central recommendation is unambiguous: hydroxyurea should be offered to every child with sickle cell anaemia from nine months of age, regardless of symptom severity. The drug reduces painful crises and prevents serious complications — but its power disappears if a child cannot swallow it, a family cannot afford it, or a health worker lacks the training to adjust doses as the child grows.
To address that reality, WHO and the Global Accelerator for Paediatric Formulations developed a Target Product Profile specifying exactly what child-friendly hydroxyurea must look like — flexible dosing, stability in hot and humid climates, practical packaging, and pricing that reflects the financial constraints of resource-limited systems. That specification now underpins WHO's first Prequalification Expression of Interest for sickle cell treatments, creating a formal quality-assurance route for manufacturers and giving procurement agencies the confidence to purchase products for national health programmes.
WHO's Dr. Pascale Allotey stated the stakes plainly: too many children are still dying from a disease for which treatments exist, and a child's birthplace should not determine whether those treatments are available. Looking further ahead, WHO is also tracking promising experimental therapies — including biologics and gene therapies — while two global networks prepare to translate recommendations into coordinated action, moving more children toward early diagnosis, reliable care, and medicines designed specifically for them.
Every year, sickle cell disease kills roughly 81,100 children under the age of five. Nearly four out of five of those deaths occur in sub-Saharan Africa, where the same children who could survive with proper treatment instead face delayed diagnosis, empty pharmacy shelves, costs their families cannot pay, and health systems stretched too thin to manage lifelong care. The World Health Organization has now released a set of clinical guidelines and a concrete pathway designed to change that arithmetic—to move quality medicines and clear treatment protocols from the realm of the known-but-unreachable into the hands of families in the countries where the burden is heaviest.
Sickle cell disease is the most common inherited blood disorder on earth. It warps the shape of red blood cells, which then move sluggishly through the body, starving tissues of oxygen and triggering cascades of pain, anemia, infections, strokes, organ failure, and premature death. The disease strikes across the globe—in the Eastern Mediterranean, the Caribbean, South Asia, Latin America, and in diaspora communities worldwide—but its weight falls hardest on low- and middle-income countries. A child diagnosed early and given access to vaccination, infection prevention, regular monitoring, and disease-modifying drugs can live a substantially healthier life. Yet those services remain unevenly scattered and financially out of reach for most households in the places where sickle cell is most common.
In May 2026, the WHO published its first guideline dedicated entirely to diagnosing, preventing, and managing sickle cell disease in children and adolescents up to age nineteen. The document contains fifteen recommendations across seven priority areas. At its center sits a strong recommendation: hydroxyurea should be offered to every child and adolescent with sickle cell anemia starting at nine months of age, regardless of how severe their symptoms appear. Hydroxyurea reduces the frequency and intensity of painful crises and prevents other serious complications—a major opportunity to prevent disability, hospital admissions, and deaths that should not happen.
But a medicine's power evaporates if a child cannot swallow it, if a family cannot afford it, or if health workers lack the training to adjust doses as the child grows. The WHO and the Global Accelerator for Paediatric Formulations identified hydroxyurea as an urgent priority during the first Paediatric Drug Optimization exercise for sickle cell disease in September 2025. By July 2026, they had published a Target Product Profile—a detailed specification of what child-friendly hydroxyurea should look like. The profile calls for formulations that children can actually take, flexible dosage strengths, stability in hot and humid climates, practical packaging, and pricing that acknowledges the financial reality of resource-limited health systems.
That specification has now shaped the WHO's first Prequalification Expression of Interest for sickle cell treatments, creating a formal route for manufacturers to submit paediatric hydroxyurea formulations and 500 mg capsules for quality evaluation. The move is designed to give governments and procurement agencies the confidence they need to purchase products for national health programs. Dr. Pascale Allotey, who directs the WHO's Department of Sexual, Reproductive, Maternal, Child and Adolescent Health and Ageing, framed the stakes plainly: too many children with sickle cell disease are still dying or enduring devastating complications even though treatments exist to help them. A child's birthplace, she said, should not determine whether treatment is available or whether that child survives to adulthood.
The WHO is also preparing for a treatment landscape that may eventually include new medicines, biologics, and gene therapies. The paediatric drug optimization exercise created a watch list of promising experimental treatments and flagged research questions that demand attention—particularly around evidence in children, affordability, and delivery in the countries carrying the greatest disease burden. Success will require coordination among governments, manufacturers, regulators, researchers, health workers, funders, procurement agencies, and the communities most affected by the disease. Two networks—the GAP-f and the forthcoming OneSCD Global Partnership—are expected to translate WHO recommendations into coordinated action, moving more children toward early diagnosis, reliable care, and medicines designed specifically for their needs.
Citas Notables
Too many children with sickle cell disease are still dying or suffering devastating complications, even though we have treatments that can help them.— Dr. Pascale Allotey, WHO Director of Sexual, Reproductive, Maternal, Child and Adolescent Health and Ageing
Quieres la nota completa?
Lee el original en Devdiscourse ↗
Health & Medicine